Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review

Diabetes mellitus (DM) and hepatic steatosis are two of the most common metabolic syndromes that affect the health of people globally. Empagliflozin (EMPA) is a promising drug of choice for the diabetic population. Recent studies have shown its beneficial effects not only on diabetic patients but al...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Fahad, Khan, Nawsheen A, Rahman, Afroza, Chowdhury, Mirza Farhana Iqbal, Bari, Sadia, Khan, Mahfuza A, Masud, Ummul Wara, Zakia, Ummul B, Paul, Shibani P, Tasnim, Nishat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506669/
https://www.ncbi.nlm.nih.gov/pubmed/36168335
http://dx.doi.org/10.7759/cureus.28367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506669/
https://www.ncbi.nlm.nih.gov/pubmed/36168335
http://dx.doi.org/10.7759/cureus.28367

Ejemplares similares